CD4-positive effector memory T cells participate in disease expression in ANCA-associated vasculitis

Annals of the New York Academy of Sciences

Volumn 1107, Issue , 2007, Pages 22-31

  Abdulahad, Wayel H ^a   Stegeman, Coen A ^a   Limburg, Pieter C ^a   Kallenberg, Cees G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

ANCA associated vasculitis; Autoimmunity; Effector memory T cells; T cells

Indexed keywords

GBM ANTIBODY; HUMAN MYELOPEROXIDASE; MONOCLONAL ANTIBODY; MYELOPEROXIDASE; UNCLASSIFIED DRUG; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ANCA ASSOCIATED VASCULITIS; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CELL SURVIVAL; CONFERENCE PAPER; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; EFFECTOR CELL; HUMAN; IMMUNIZATION; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; MULTIPLE SCLEROSIS; NONHUMAN; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; UPREGULATION; WEGENER GRANULOMATOSIS; ANIMAL; ARTICLE; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; PATHOLOGY; PHENOTYPE; VASCULITIS;

ANIMALS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; CD4-POSITIVE T-LYMPHOCYTES; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNOLOGIC MEMORY; PHENOTYPE; VASCULITIS;

EID: 34648846035     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1381.003     Document Type: Conference Paper

References (54)

1. JENNETTE, J.C. & R.J. FALK. 1997. Small-vessel vasculitis. N. Engl. J. Med. 337: 1512-1523.
2. SAVAGE, C.O., L. HARPER & D. ADU. 1997. Primary systemic vasculitis. Lancet 349: 553-558.
3. KALLENBERG, C.G. 2005. Churg-Strauss syndrome: just one disease entity? Arthritis Rheum. 52: 2589-2593.
4. ARA, J., E. MIRAPEIX, R. RODRINGUEZ, et al. 1999. Relationship between ANCA and disease activity in small vessel vasculitis patients with anti-MPO ANCA. Nephrol. Dial. Transplant. 14: 1667-1672.
5. XIAO, H., P. HEERINGA, P. HU, et al. 2002. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J. Clin. Invest 110: 955-963.
6. BROUWER, E., J.W. COHEN TERVAERT, G. HORST, et al. 1991. Predominance of IgG1 and IgG4 subclasses of anti-neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener's granulomatosis and clinically related disorders. Clin. Exp. Immunol. 83: 379-386.
7. GEPHARDT, G.N., M. AHMAD & R.R. TUBBS. 1983. Pulmonary vasculitis(Wegener's granulomatosis). Immunohistochemical study of T and B cell markers. Am. J. Med. 74: 700-704.
8. TEN BERGE, I.J., J.M. WILMINK, C.J. MEYER, et al. 1985. Clinical and immunological follow-up of patients with severe renal disease in Wegener's granulomatosis. Am. J. Nephrol. 5: 21-29.
9. BOLTON, W.K., D.J. INNES Jr., B.C. STURGILL, et al. 1987. T-cells and macrophages in rapidly progressive glomerulonephritis: clinicopathologic correlations. Kidney Int. 32: 869-876.
10. SAVAGE, C.O., L. HARPER & M. HOLLAND. 2002. New findings in pathogenesis of antineutrophil cytoplasm antibody-associated vasculitis. Curr. Opin. Rheumatol. 14: 15-22.
11. LOCKWOOD, C.M., S. THIRU, S. STEWART, et al. 1996. Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. Q. J. Med. 89: 903-912.
12. HAGEN, E.C., R.J. DE KEIZER, K. ANDRASSY, et al. 1995. Compassionate treatment of Wegener's granulomatosis with rabbit anti-thymocyte globulin. Clin. Nephrol. 43: 351-359.
13. BROUWER, E., C.A. STEGEMAN, M.G. HUITEMA, et al. 1994. T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis (WG). Clin. Exp. Immunol. 98: 448-453.
14. MATHIESON, P.W. & D.B. OLIVEIRA. 1995. The role of cellular immunity in systemic vasculitis. Clin. Exp. Immunol. 100: 183-185.
15. POPA, E.R., C.A. STEGEMAN, N.A. BOS, et al. 1999. Differential B- and T-cell activation in Wegener's granulomatosis. J. Allergy Clin. Immunol. 103: 885-894.
16. SCHONERMARCK, U., E. CSERNOK, A. TRABANDT, et al. 2000. Circulating cytokines and soluble CD23, CD26 and CD30 in ANCA-associated vasculitides. Clin. Exp. Rheumatol. 18: 457-463.
17. SANDERS, J.S., C.A. STEGEMAN & C.G. KALLENBERG. 2003. The Th1 and Th2 paradigm in ANCA-associated vasculitis. Kidney Blood Press. Res. 26: 215-220.
18. GISCOMBE, R., S. NITYANAND, N. LEWIN, et al. 1998. Expanded T cell populations in patients with Wegener's granulomatosis: characteristics and correlates with disease activity. J. Clin. Immunol. 18: 404-413.
19. GISCOMBE, R., X.B. WANG, M. KAKOULIDOU, et al. 2006. Characterization of the expanded T-cell populations in patients with Wegener's granulomatosis. J. Intern. Med. 260: 224-230.
20. KOMOCSI, A., P. LAMPRECHT, E. CSERNOK, et al. 2002. Peripheral blood and granuloma CD4(+)CD28(-) T cells are a major source of interferon-gamma and tumor necrosis factor-alpha in Wegener's granulomatosis. Am. J. Pathol. 160: 1717-1724.
21. MOOSIG, F., E. CSERNOK, G. WANG, et al. 1998. Costimulatory molecules in Wegener's granulomatosis (WG): lack of expression of CD28 and preferential upregulation of its ligands B7-1 (CD80) and B7-2 (CD86) on T cells. Clin. Exp. Immunol. 114: 113-118.
22. STEINER, K., F. MOOSIG, E. CSERNOK, et al. 2001. Increased expression of CTLA-4 (CD152) by T and B lymphocytes in Wegener's granulomatosis. Clin. Exp. Immunol. 126: 143-150.
23. LAMPRECHT, P., A. ERDMANN, A. MUELLER, et al. 2003. Heterogeneity of CD4 and CD8+ memory T cells in localized and generalized Wegener's granulomatosis. Arthritis Res. Ther. 5: R25-R31.
24. LAMPRECHT, P., H. BRUHL, A. ERDMANN, et al. 2003. Differences in CCR5 expression on peripheral blood CD4+CD28- T-cells and in granulomatous lesions between localized and generalized Wegener's granulomatosis. Clin. Immunol. 108: 1-7.
25. COULOMB-L'HERMINE, A., F. CAPRON, W. ZOU, et al. 2001. Expression of the chemokine RANTES in pulmonary Wegener's granulomatosis. Hum. Pathol. 32: 320-326.
26. LAMPRECHT, P., F. MOOSIG, E. CSERNOK, et al. 2001. CD28 negative T cells are enriched in granulomatous lesions of the respiratory tract in Wegener's granulomatosis. Thorax 56: 751-757.
27. IEZZI, G., D. SCHEIDEGGER & A. LANZAVECCHIA. 2001. Migration and function of antigen-primed nonpolarized T lymphocytes in vivo. J. Exp. Med. 193: 987-993.
28. SALLUSTO, F., J. GEGINAT & A. LANZAVECCHIA. 2004. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22: 745-763.
29. ZAPH, C., J. UZONNA, S.M. BEVERLEY, et al. 2004. Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites. Nat. Med. 10: 1104-1110.
30. SALLUSTO, F., D. LENIG, R. FOSTER, et al. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708-712.
31. BURNS, J., B. BARTHOLOMEW & S. LOBO. 1999. Isolation of myelin basic protein-specific T cells predominantly from the memory T-cell compartment in multiple sclerosis. Ann. Neurol. 45: 33-39.
32. WULFF, H., P.A. CALABRESI, R. ALLIE, et al. 2003. The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. J. Clin. Invest. 111: 1703-1713.
33. VIGLIETTA, V., S.C. KENT, T. ORBAN, et al. 2002. GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes. J. Clin. Invest. 109: 895-903.
34. FRIEDRICH, M., S. KRAMMIG, M. HENZE, et al. 2000. Flow cytometric characterization of lesional T cells in psoriasis: intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype. Arch. Dermatol. Res. 292: 519-521.
35. GATTORNO, M., I. PRIGIONE, F. MORANDI, et al. 2005. Phenotypic and functional characterisation of CCR7+ and CCR7- CD4+ memory T cells homing to the joints in juvenile idiopathic arthritis. Arthritis Res. Ther. 7: R256-R267.
36. BEETON, C., H. WULFF, J. BARBARIA, O. CLOT-FAYBESSE, et al. 2001. Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc. Natl. Acad. Sci. USA 98: 13942-13947.
37. ABDULAHAD, W.H., Y.M. VAN DER GELD, C.A. STEGEMAN, et al. 2006. Persistent expansion of CD4+ effector memory T cells in Wegener's granulomatosis. Kidney Int. 70: 938-947.
38. CARUSO, A.M., N. SERBINA, E. KLEIN, et al. 1999. Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis. J. Immunol. 162: 5407-5416.
39. DI PERRI, G., A. CAZZADORI, S. VENTO, et al. 1996. Comparative histopathological study of pulmonary tuberculosis in human immunodeficiency virus-infected and non-infected patients. Tuber. Lung Dis. 77: 244-249.
40. RUTH, A.J., A.R. KITCHING, R.Y. KWAN, et al. 2006. Anti-neutrophil cytoplasmic antibodies and effector CD4+ cells play nonredundant roles in antimyeloperoxidase crescentic glomerulonephritis. J. Am. Soc. Nephrol. 17: 1940-1949.
41. MARINAKI, S., A.I. KALSCH, P. GRIMMINGER, et al. 2006. Persistent T-cell activation and clinical correlations in patients with ANCA-associated systemic vasculitis. Nephrol. Dial. Transplant. 21: 1825-1832.
42. SAKATSUME, M. & F. GEJYO. 2003. Effector T cells and macrophages in urine as a hallmark of systemic vasculitis accompanied by crescentic glomerulonephritis. Nephrol. Dial. Transplant. 18: 607-609.
43. SAKATSUME, M., Y. XIE, M. UENO, et al. 2001. Human glomerulonephritis accompanied by active cellular infiltrates shows effector T cells in urine. J. Am. Soc. Nephrol. 12: 2636-2644.
44. STEGEMAN, C.A., J.W. COHEN TERVAERT, W.J. SLUITER, et al. 1994. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann. Intern. Med. 120: 12-17.
45. MAYET, W.J., E. MARKER-HERMANN, J. SCHLAAK, et al. 1999. Irregular cytokine pattern of CD4+ T lymphocytes in response to Staphylococcus aureus in patients with Wegener's granulomatosis. Scand. J. Immunol. 49: 585-594.
46. POPA, E.R., C.F. FRANSSEN, P.C. LIMBURG, et al. 2002. In vitro cytokine production and proliferation of T cells from patients with anti-proteinase 3- and antimyeloperoxidase-associated vasculitis, in response to proteinase 3 and myeloperoxidase. Arthritis Rheum. 46: 1894-1904.
47. ABDULAHAD, W.H., C.A. STEGEMAN, Y.M. VAN DER GELD, et al. 2007. Functional defect of circulating regulatory CD4 + T cells in patients with Wegener's granulomatosis in remission. Arthritis Rheum. 56: 2080-2091.
48. HANSSON, H.A., B. PETRUSON & K. PETRUSON. 1989. Immunohistochemical demonstration of insulin-like growth factor I in inflammatory lesions in Wegener's granulomatosis and idiopathic midline destructive disease. Scand. J. Rheumatol. 18: 133-141.
49. TU, W., P.T. CHEUNG & Y.L. LAU. 2000. Insulin-like growth factor 1 promotes cord blood T cell maturation and inhibits its spontaneous and phytohemagglutinin-induced apoptosis through different mechanisms. J. Immunol. 165: 1331-1336.
50. PANDIYAN, P., D. GARTNER, O. SOEZERI, et al. 2004. CD152 (CTLA-4) determines the unequal resistance of Th1 and Th2 cells against activation-induced cell death by a mechanism requiring PI3 kinase function. J. Exp. Med. 199: 831-842.
51. JAGELLO, P., P. ARIES, L. ARNING, et al. 2005. The PTPN22 620W allele is a risk factor for Wegener's granulomatosis. Arthritis Rheum. 52: 4039-4043.
52. MUSTELIN, T., A. ALONSO, N. BOTTINI, et al. 2004. Protein tyrosine phosphatases in T cell physiology. Mol. Immunol. 41: 687-700.
53. BEETON, C., J. BARBARIA, P. GIRAUD, et al. 2001. Selective blocking of voltagegated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. J. Immunol. 166: 936-944.
54. BEETON, C., H. WULFF, N.E. STANDIFER, et al. 2006. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc. Natl. Acad. Sci. USA 103: 17414-17419.